344 related articles for article (PubMed ID: 36351411)
1. Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis.
Won T; Kalinoski HM; Wood MK; Hughes DM; Jaime CM; Delgado P; Talor MV; Lasrado N; Reddy J; Čiháková D
Cell Rep; 2022 Nov; 41(6):111611. PubMed ID: 36351411
[TBL] [Abstract][Full Text] [Related]
2. Exacerbation of autoimmune myocarditis by an immune checkpoint inhibitor is dependent on its time of administration in mice.
Tsuruoka K; Wakabayashi S; Morihara H; Matsunaga N; Fujisaka Y; Goto I; Imagawa A; Asahi M
Int J Cardiol; 2020 Aug; 313():67-75. PubMed ID: 32402518
[TBL] [Abstract][Full Text] [Related]
3. Heart-Specific Immune Responses in an Animal Model of Autoimmune-Related Myocarditis Mitigated by an Immunoproteasome Inhibitor and Genetic Ablation.
Bockstahler M; Fischer A; Goetzke CC; Neumaier HL; Sauter M; Kespohl M; Müller AM; Meckes C; Salbach C; Schenk M; Heuser A; Landmesser U; Weiner J; Meder B; Lehmann L; Kratzer A; Klingel K; Katus HA; Kaya Z; Beling A
Circulation; 2020 Jun; 141(23):1885-1902. PubMed ID: 32160764
[TBL] [Abstract][Full Text] [Related]
4. T cells specific for α-myosin drive immunotherapy-related myocarditis.
Axelrod ML; Meijers WC; Screever EM; Qin J; Carroll MG; Sun X; Tannous E; Zhang Y; Sugiura A; Taylor BC; Hanna A; Zhang S; Amancherla K; Tai W; Wright JJ; Wei SC; Opalenik SR; Toren AL; Rathmell JC; Ferrell PB; Phillips EJ; Mallal S; Johnson DB; Allison JP; Moslehi JJ; Balko JM
Nature; 2022 Nov; 611(7937):818-826. PubMed ID: 36385524
[TBL] [Abstract][Full Text] [Related]
5. Protective effect of low-intensity pulsed ultrasound on immune checkpoint inhibitor-related myocarditis via fine-tuning CD4
Fu S; Guo Z; Xu X; Li Y; Choi S; Zhao P; Shen W; Gao F; Wang C; Chen S; Li Y; Tian J; Sun P
Cancer Immunol Immunother; 2024 Jan; 73(1):15. PubMed ID: 38236243
[TBL] [Abstract][Full Text] [Related]
6. Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis.
Zhu H; Galdos FX; Lee D; Waliany S; Huang YV; Ryan J; Dang K; Neal JW; Wakelee HA; Reddy SA; Srinivas S; Lin LL; Witteles RM; Maecker HT; Davis MM; Nguyen PK; Wu SM
Circulation; 2022 Jul; 146(4):316-335. PubMed ID: 35762356
[TBL] [Abstract][Full Text] [Related]
7. Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program.
Naqash AR; Moey MYY; Cherie Tan XW; Laharwal M; Hill V; Moka N; Finnigan S; Murray J; Johnson DB; Moslehi JJ; Sharon E
J Clin Oncol; 2022 Oct; 40(29):3439-3452. PubMed ID: 35658474
[TBL] [Abstract][Full Text] [Related]
8. Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature.
Boutros A; Bottini A; Rossi G; Tanda ET; Spagnolo F; Barletta G; Croce E; Fava P; Parisi A; De Rosa F; Palla M; Marconcini R; Ferrari M; Grandis M; Spallarossa P; Sarocchi M; Arboscello E; Del Mastro L; Lambertini M; Pronzato P; Genova C
ESMO Open; 2023 Feb; 8(1):100791. PubMed ID: 36791639
[TBL] [Abstract][Full Text] [Related]
9. Myocarditis in Cynomolgus Monkeys Following Treatment with Immune Checkpoint Inhibitors.
Ji C; Roy MD; Golas J; Vitsky A; Ram S; Kumpf SW; Martin M; Barletta F; Meier WA; Hooper AT; Sapra P; Khan NK; Finkelstein M; Guffroy M; Buetow BS
Clin Cancer Res; 2019 Aug; 25(15):4735-4748. PubMed ID: 31085720
[TBL] [Abstract][Full Text] [Related]
10. Immunopathogenesis of Immune Checkpoint Inhibitor Induced Myocarditis: Insights from Experimental Models and Treatment Implications.
Wong CK; Lam TH; Liao SY; Lau YM; Tse HF; So BYF
Biomedicines; 2023 Jan; 11(1):. PubMed ID: 36672615
[TBL] [Abstract][Full Text] [Related]
11. Expansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis.
Ma P; Liu J; Qin J; Lai L; Heo GS; Luehmann H; Sultan D; Bredemeyer A; Bajapa G; Feng G; Jimenez J; He R; Parks A; Amrute J; Villanueva A; Liu Y; Lin CY; Mack M; Amancherla K; Moslehi J; Lavine KJ
Circulation; 2024 Jan; 149(1):48-66. PubMed ID: 37746718
[TBL] [Abstract][Full Text] [Related]
12. TNF-α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis.
Liu X; Wu W; Fang L; Liu Y; Chen W
Front Immunol; 2022; 13():922782. PubMed ID: 35844550
[TBL] [Abstract][Full Text] [Related]
13. ANGPTL2 promotes immune checkpoint inhibitor-related murine autoimmune myocarditis.
Horiguchi H; Kadomatsu T; Yamashita T; Yumoto S; Terada K; Sato M; Morinaga J; Miyata K; Oike Y
Commun Biol; 2023 Sep; 6(1):965. PubMed ID: 37736764
[TBL] [Abstract][Full Text] [Related]
14. Role of Biomarkers in the Management of Immune-Checkpoint Inhibitor-Related Myocarditis.
Vasbinder A; Ismail A; Salem JE; Hayek SS
Curr Cardiol Rep; 2023 Sep; 25(9):959-967. PubMed ID: 37436648
[TBL] [Abstract][Full Text] [Related]
15. An Autopsy Case of Late-onset Fulminant Myocarditis Induced by Nivolumab in Gastric Cancer.
Naganuma K; Horita Y; Matsuo K; Miyama Y; Mihara Y; Yasuda M; Nakano S; Hamaguchi T
Intern Med; 2022 Oct; 61(19):2867-2871. PubMed ID: 35249925
[TBL] [Abstract][Full Text] [Related]
16. [Clinical features of immune checkpoint inhibitor-related myositis in patients with urological cancer].
Ying YC; Tang Q; Yang KW; Mi Y; Fan Y; Yu W; Song Y; He ZS; Zhou LQ; Li XS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):644-651. PubMed ID: 35950386
[TBL] [Abstract][Full Text] [Related]
17. A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma.
Matsui H; Kawai T; Sato Y; Ishida J; Kadowaki H; Akiyama Y; Yamada Y; Nakamura M; Yamada D; Akazawa H; Suzuki M; Komuro I; Kume H
Int Heart J; 2020 Sep; 61(5):1070-1074. PubMed ID: 32921673
[TBL] [Abstract][Full Text] [Related]
18. Immune tolerance to cardiac myosin induced by anti-CD4 monoclonal antibody in autoimmune myocarditis rats.
Wang QQ; Wang YL; Yuan HT; Liu FQ; Jin YP; Han B
J Clin Immunol; 2006 May; 26(3):213-21. PubMed ID: 16783461
[TBL] [Abstract][Full Text] [Related]
19. Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study.
Xie X; Wang L; Li Y; Xu Y; Wu J; Lin X; Lin W; Mai Q; Chen Z; Zhang J; Xie Z; Qin Y; Liu M; Lu M; Luo B; Zhou C
Front Immunol; 2022; 13():879900. PubMed ID: 35924238
[TBL] [Abstract][Full Text] [Related]
20. Myosin autoimmunity is not essential for cardiac inflammation in acute Chagas' disease.
Leon JS; Wang K; Engman DM
J Immunol; 2003 Oct; 171(8):4271-7. PubMed ID: 14530351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]